{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:17:03Z","timestamp":1788542223058,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cllc.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T19:55:55Z","timestamp":1555703755000},"page":"e489-e491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Matthew S.","family":"Lara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Afify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinh T.","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.04.007_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cllc.2019.04.007_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.04.007_bib3","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.1999.17.7.2280","article-title":"Thymoma: state of the art","volume":"17","author":"Thomas","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.04.007_bib4","first-page":"116","article-title":"Myasthenia gravis: changes observed in a 30-years retrospective clinical study of a hospital-based population","volume":"251","author":"Potagas","year":"2004","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cllc.2019.04.007_bib5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: a long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cllc.2019.04.007_bib6","doi-asserted-by":"crossref","unstructured":"Cho J, Kim HS, Ku BM, et\u00a0al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial [e-pub head of print]. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.77.3184.","DOI":"10.1200\/JCO.2017.77.3184"},{"key":"10.1016\/j.cllc.2019.04.007_bib7","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.jtho.2016.11.333","article-title":"Safety and clinical activity of avelumab (MSB0010718C; anti-PD-L1) in patients with advanced thymic epithelial tumors (TETs)","volume":"12","author":"Rajan","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.04.007_bib8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.cllc.2019.04.007_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419300877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419300877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:09:55Z","timestamp":1761505795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419300877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1525730419300877"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.04.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}